Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy

INTRODUCTION: Monotherapy with darunavir plus ritonavir (DRV/r) is a good maintenance strategy for suppressed HIV-infected patients. The clinical trials designed to prove the efficacy of PI/r do not include patients with resistance mutation in protease gene [1,2]. Sometimes in routine practice, basi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez-Liarte, Angela, Gomez-Berrocal, Ana, Saez, Carmen, Valencia, Jorge, Santos, Ignacio, Sanz, Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P228
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225381/
https://www.ncbi.nlm.nih.gov/pubmed/25397505
http://dx.doi.org/10.7448/IAS.17.4.19760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225381/
https://www.ncbi.nlm.nih.gov/pubmed/25397505
http://dx.doi.org/10.7448/IAS.17.4.19760

Ejemplares similares